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Abstract
Rett syndrome (RTT) is a rare disease but still one of the most abundant causes for intellectual disability in females.
Typical symptoms are onset at month 6–18 after normal pre- and postnatal development, loss of acquired skills and
severe intellectual disability. The type and severity of symptoms are individually highly different. A single mutation
in one gene, coding for methyl-CpG-binding protein 2 (MECP2), is responsible for the disease. The most important
action of MECP2 is regulating epigenetic imprinting and chromatin condensation, but MECP2 influences many
different biological pathways on multiple levels although the molecular pathways from gene to phenotype are
currently not fully understood. In this review the known changes in metabolite levels, gene expression and
biological pathways in RTT are summarized, discussed how they are leading to some characteristic RTT phenotypes
and therefore the gaps of knowledge are identified. Namely, which phenotypes have currently no mechanistic
explanation leading back to MECP2 related pathways? As a result of this review the visualization of the biologic
pathways showing MECP2 up- and downstream regulation was developed and published on WikiPathways which
will serve as template for future omics data driven research. This pathway driven approach may serve as a use case
for other rare diseases, too.
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Background
Rett syndrome (RTT; MIM:312750) occurs in 1:10.000
girls at the age of 12 [1]. It is considered a rare disease
since it affects fewer than 1 in 2000 individuals [2], but
it is still one of the most abundant causes for intellectual
disability in females. RTT was first described in 1966 by
the Viennese pediatric Andreas Rett, who observed the
typical hand movements (“hand washing”) of his patients
[3, 4]. Cause of RTT is in most cases a de novo mutation
of MECP2 (methyl-CpG-binding protein 2) gene; which
was discovered by Amir et al. [5]. However, as stated by
Neul et al., “not all mutations in MECP2 cause RTT and
not all RTT patients have mutated MECP2”. Some
MECP2 mutations cause not RTT but a mild intellectual
disability [6] and mutations in two other genes can cause
a RTT like phenotype, i.e. FOXG1 and CDKL5. These
phenotypes were formerly considered as RTT but are
now defined as RTT like syndrome [7].
RTT was considered a neurodevelopmental disorder
but since some of the main symptoms were found to
be reversible [8] researchers and clinicians tend to
categorize it as a neurological disorder now [9]. RTT
was also classified as an autism spectrum disorder as
patients often develop autistic features like social with-
drawal but only during a certain stage of development
[10]. Although RTT has some autistic features/phases
these usually disappear with time and adult RTT fe-
males are quite socially active again [11]. MECP2 mu-
tations are rarely found in autism patients and if, they
are termed “Autism with MECP2 mutation” [7].
Recent research was able to find a correlation between
certain MECP2 mutations (or MECP2 variants) and
some phenotypes, e.g. cardiorespiratory phenotype [12],
but most of the biological pathways between gene and
phenotype are not yet fully understood. Especially the
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molecular pathways leading from MECP2 gene to scoli-
osis, epilepsy or decreased growth are currently not
known. In this review, we summarize the knowledge
about the molecular interactions of MECP2 gene and
protein, their known downstream effects and discuss
how pathway and omics data based research can eluci-
date the pathways towards RTT phenotypes. This re-
view integrates database knowledge from Ensembl [13],
OMIM [14], UniProt [15], The Human Protein Atlas
[16], and Gene Ontology [17] and a biologic pathway
was developed and published on WikiPathways [18] to
visualize the mechanistic action of MECP2 and serve as
a template for future omics data analysis also in other
rare disease models.
Rett syndrome phenotype development within life
Typical development of RTT starts with an “asymptom-
atic” first stage followed by decreased, arrested and re-
tarded development of motor and communication skills
after 6–18 months of normal postnatal development, de-
velopment of stereotypic movements and loss of pur-
poseful movement. Although the onset of typical
disorder symptoms after the age of 6 months is charac-
teristic for RTT, observations of parents that “something
is wrong with this child”, are often made before. This
matches with newer research which indicates that severe
changes in neuronal development are apparent already
at this age but due to their mild and uncertain symp-
toms not able to be diagnosed [19]. After a stagnation
stage (2 – 10 years) which can last for years and can in-
clude some recovery and secondary gain of abilities the
fourth stage typically reduces again mobility (by abnor-
mal muscle tonus and scoliosis) while communication
and cognition is preserved. RTT females are typically se-
verely intellectual disabled, have microcephaly and sei-
zures. Additionally, they often develop symptoms like
cardiac and breathing abnormalities, gastro-intestinal
problems like constipation, low muscle tension, autistic
like behavior, scoliosis (and other osteopathies), sleeping
problems and hormone disequilibrium. In summary,
MECP2 affects epigenetic regulation of gene expression,
which changes neurobiological activity, network forma-
tion and function, which causes the major phenotype. In
summary, MECP2 affects epigenetic regulation of gene
expression, which changes neurobiological activity, net-
work formation and function, which causes the major
phenotype. Recent longitudinal studies on the lifelong
development of RTT stated that survival at the age of
25 years was 77.6% and 59.8% at 37 years [20]. The most
abundant causes of death were lower respiratory tract
infection, aspiration/asphyxication and respiratory fail-
ure. Two-thirds of RTT females had seizures on some
point in their lives of which 36.1% were drug resistant
[20]. About half of the females completely lost the ability
to walk while independent walking was preserved in
17.8%. Scoliosis (85.5%) and abnormal breathing patterns
(up to 88.7%) were very abundant [20]. Typical notice-
able laboratory results are EEG (and EKG) abnormal-
ities, atypical brain glycolipids, altered neurotransmitter,
creatine and growth factor levels, and alkalosis. Most of
the symptoms can be related to disturbed neuronal func-
tion but some of them are caused or influenced by alter-
ations which are not yet elucidated [4, 21, 22]. It is also
unknown whether it is the often in RTT observed
changes of carbon dioxide metabolism that cause re-
spiratory problems or that dysfunctional brain stem neu-
rons are responsible for breathing abnormality [4].
MECP2 gene, transcript and protein
The MECP2 gene is highly conserved in Euteleostomi
(bony vertebrates). The NCBI HomoloGene/UniGene
database gives detailed information about gene homo-
logues in 10 mammalian, 2 amphibian and 1 bony fish
species [23]. The human MECP2 is located on chromo-
some X, position 154,021,573-154,137,103 (reverse strand)
(according to Ensembl, version 84, genome build
GRCh38.p5 (GCA_000001405.20)) and there are currently
21 transcripts known, two of these are protein coding
(Fig. 1). Due to dosage compensation MECP2 is inacti-
vated in one X-chromosome in females and the degree of
inactivation is assumed to contribute to the difference in
phenotypes for RTT [24]. RTT is more often observed in
females due to its location on the X-chromosome. Hemi-
zygous males with a severe mutation are generally not vi-
able, but there are several non-lethal mutations which
can lead to severe congenital encephalopathy, RTT-like
syndrome, and mild to severe intellectual disability in
males [25]. Mosaic expression with only wild-type
MECP2 active in females are possible but supposed to
be extremely rare [24].
The transcription and translation of MECP2 is highly
regulated [26] (Table 1 and Fig. 2). There are several cis-
and trans-regulatory elements for MECP2 gene expres-
sion regulation known. Cis regulatory elements, includ-
ing promotor elements, are loci on the DNA which act
as binding sites for transcription factors and activate or
repress gene expression. Trans-elements affect the regu-
lation in an indirect way and can be located close or far
away. They can for instance include genes that encode
transcription factors for this specific gene. Translation
of MECP2 can be regulated by a set of microRNAs
[27–35]. MicroRNAs are small non-coding RNAs, that
repress translation mRNA into protein by binding to
the 3’ untranslated region of the mRNA. The regulation
of MECP2 expression, stimulation and repression, is vi-
sualized in Fig. 2 (transcriptional and translational
regulation of MECP2) which is derived from WikiPath-
ways [18] pathway ID 3584.
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The two coding transcripts are isoforms of MECP2,
long e1 and short e2, while e1 seems to be the more im-
portant one [36, 37] (Fig. 1). Itoh et al. observed that
specific deactivation of e2 did not influence normal neu-
rodevelopment while loss of e1 led to RTT [38]. The
MECP2 protein has at least six biochemically distinct
domains [39]. Two of them are most important for the
protein function: the (84 amino acids) methyl-CpG bind-
ing domain (MDB) which is the one which selectively
binds 5MeCyt and the transcriptional repression do-
main (TRD) (102 amino acids) which binds cofactors
attracting histone deacetylase and finally leading to
transcription repression as explained in the chapter 4
(Fig. 1) [39, 40]. Interestingly, MBD is the only struc-
tured domain (α-helix) while 60% of MECP2 is unstruc-
tured [39]. There are several post translational
modifications of MECP2 known which contribute to its
multi-functional properties, phosphorylation, acetyl-
ation, SUMOylation, and ubiquitination [41].
MECP2 protein is most abundant in brain but also
enriched in lung and spleen tissue [42]. However, ac-
cording to The Human Protein Atlas database MECP2
protein (and its transcript) is found in quite high
amounts in almost every tissue, too. This may actually
be the most underestimated part in RTT research which
typically focus on neuronal development and function
[16]. Many phenotypes and symptoms may be as well
deriving from dysfunctional cellular regulation in other
organs than central nervous system. In neurons an ex-
pression level of about 1.6x107 protein copies per nu-
cleus was estimated by Skene et al. It is about the same
number as nucleosomes or 5-methyl-cytosine (5MeCyt)
spots on the DNA, leading to the suggestion that every
spot might be covered by one MECP2 [43].
MECP2 function
MECP2 is a multifunctional protein which influences
gene expression and metabolism on many levels [9]
(Fig. 3). The main function of MECP2 is to recognize
and bind specifically methylated cytosine residues in
the DNA (namely 5MeCyt) that are enriched with A/
T bases adjacent [44]. MECP2 binds also but with
lesser affinity to hydroxymethylated DNA (namely 5-
hydroxy methylated cytosine, 5OHMeCyt). Mutations
in MECP2, especially in the MDB, which lead to loss
of specific 5MeCyt binding functions are known to
cause RTT [45] (Fig. 1).
Table 1 Regulation of MECP2 expression by transcription factors and microRNA
Type Transcription factors/microRNA
Transcription factors targeting MECP2 cis-elements [27–29] Activation by BRN3, MYT1, SP1, SP3, C/EBP, CTCF, E2F1, TAF1, TAP1
Repression by REST, BRN2, BCL6,
Trans-regulatory elements of MECP2 [30] Activation by HNRNPF
Repression by HNRNPH1
miRNA (posttranscriptional repression) [31–35] hsa-miR-483- 5p, hsa-miR-132-5p, hsa-miR-152-3p, hsa-miR-199a-3p,
hsa-miR-30a-3p, and hsa-miR-130b-3p
Fig. 1 MECP2 gene and protein. MECP2 is located on the X chromosome (X:154021573–154137103) on the reverse strand (ensembl, human
genome built 8.2). MECP2 gene is about 10505 bp long and has 4 exons which can be spliced to two protein-coding variants e1 and e2. The
protein has 498 (486) amino acids and consists of 6 distinct domains whereas the methyl-DNA binding (MDB) and the transcriptional repression
domain (TRD) are the most important for function. Mutation positions are marked with red arrows according to Lyst et al. 2013 [57]. Solid red
arrows indicate position of mutations of MECP2, which are present in Rett females but not in their parents. Those are found mostly in MDB and
the C-terminal end of TRD. Empty red arrows indicate MECP2 mutations, which do not lead to Rett syndrome. The major phorphorylation sites
(S80 and S241) are marked in black [118]
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This is in line with the Gene Ontology classification
for the main molecular functions of MECP2: DNA bind-
ing, namely double-stranded methylated DNA and pro-
tein binding, namely histone deacetylase. The actual full
Gene Ontology annotation of MECP2 can be found on-
line e.g. Ensembl database MECP2 entry [13].
The molecular functions of MECP2 are known to in-
fluence various biological mechanisms, which are sum-
marized and visualized in the pathway Fig. 2, namely 1)
MECP2 influences global translation by enhancing the
AKT/mTOR signaling pathway [46], 2) Alternative spli-
cing of downstream gene products is affected because
MECP2 forms a complex with YB1, an important spli-
cing factor [29, 47–51], 3) Expression of various micro-
RNAs and long non-coding RNAs is regulated by
MECP2 (20, 45, 47–49), and 4) MECP2 triggers the
chromatin compaction at methylated DNA sites which
regulates the transcription of adjacent genes (34, 37–41).
The last one is an important (and best investigated)
pathway and will be explained in detail below.
MECP2 as epigenetic regulator
Methylation of DNA is part of epigenetic gene expres-
sion regulation, where DNA is modified without chan-
ging the genetic code. Most transcription factors are
unable to bind to methylated DNA so methylation usu-
ally silences a gene. Furthermore, methylated DNA is –
via MECP2 mediated cofactor binding - a binding site
for histone deacetylase (HDAC) which increases DNA
compaction by removing certain acetyl residues from ly-
sine at the histone tail allowing them to get closer to
each other (Fig. 2, MECP2-HDAC complex). So, methyl-
ated DNA is tightly wrapped around histone proteins
and the access of transcription factors is physically
Fig. 2 MECP2 pathway from WikiPathways (wikipathways.org/instance/WP3584). Visualization of MECP2 is regulated by several upstream elements, e.g.
promotor elements and microRNAs, and MECP2 regulating the expression and splicing of several downstream transcripts, proteins and miRNAs
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inhibited [40]. About 1% of DNA is methylated in
humans and the methylation sites are often in regions
with a high occurrence of CG, so-called CpG islands.
CpG islands are present in the promotor regions of most
human genes (60%). Methylation patterns play a role
in cellular differentiation and tissue specific gene ex-
pression already during early development [52–54].
The methylation pattern is continuously modified and
maintained during mitosis and cell differentiation
throughout life to grant cellular function [55, 56].
Figure 4 visualizes this circular pathway of DNA
methylation, hydroxylation and de-methylation and
shows the mode of action of involved proteins includ-
ing MECP2.
MECP2 recognizes and binds specifically to 5MeCyt
present in DNA. After binding it attracts co-repressor
Fig. 3 MECP2 and its different levels of influence to chromatin structure, DNA binding, protein and metabolite level leading to clinical phenotypes.
5MeCyt =methylated cytosine, 5OHMeCyt = hydroxylated cytosine
Fig. 4 Pathway of cytosine methylation. 5MeCyt is converted to 5OHMeCyt and further to 5-formylcytosine and 5-carboxycytosine by the TET1-3
complex. MECP2 binding to these sites prevents them from being converted. The biological process is available at wikipathways.org/instance/WP3585
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complexes containing SIN3A, NCOR and SMRT. This co-
repressor complex finally recruits histone deacetylase
(HDAC) [29, 40, 47, 57] (Fig. 2, see MECP2 – HDAC com-
plex). The complex acts by removing certain acetyl groups
from histone proteins leading to chromatin condensation
around methylated DNA [58, 59]. Cell culture experiments
with an inhibitor of HDAC resulted in the same phenotype
as MECP2-KO cells [60]. The NCOR-SMRT interaction
domain (NID) of MECP2 is located within the TRD do-
main and the association with NCOR-SMRT is responsible
for transcription repression activity of MECP2.
MECP2 was generally considered as a transcription in-
hibitor but recent research found also a conditional tran-
scription activation function. Skene et al. identified
MECP2, because of its mere amount, being equal to
number of histone octamers or methylated DNA sites,
as a global damper of gene transcription in mature
mouse brain cells [43]. During MECP2 absence H3 (his-
tone family 3) acetylation levels were globally elevated
and H1 (histone family 1) levels doubled suggesting
MECP2 alters global chromatin state towards condensa-
tion and represses transcription. Li et al. on the other
hand found global transcription activation by MECP2 in
human embryonic stem cells which underwent differen-
tiation to neuronal cells but repression by MECP2 in
mature neuronal cells indicating that MECP2 can be
both, an activator and repressor [61]. The activation
mechanism is explained as follows: MECP2 recruits
CREB1 as a cofactor to target gene promotors [62] (Fig. 2,
Activation of transcription). MECP2 binding to 5OHMe-
Cyt was even interpreted as a marker of active genes in
neurons [62]. MECP2 was also found to form a TET1 con-
taining complex which leads to 5MeCyt hydroxylation
and further to demethylation of DNA, enabling transcrip-
tion [63]. This mechanism was found to activate expres-
sion of downstream genes, namely BDNF, SST, OPRK1,
GAMT, GPRIN1, and CREB1 [28] and is contradictory to
other findings which describe MECP2 to block DNA de-
methylation by TET complex (Fig. 4) [64].
MECP2 is additionally responsible for neuronal activity
triggered transcription. Neuronal membrane depolarization
and Ca2+ influx leads to phosphorylation of MECP2 which
makes it detach from DNA, allowing decondensation and
transcription (Fig. 2) [65–69]. Specific blocking of MECP2
phosphorylation sites led to RTT like symptoms [70].
For a conclusion, MECP2 is responsible for the epigen-
etic regulation of gene expression, which changes
neurobiological activity, network formation and func-
tion which is likely to cause a severe disorder pheno-
type if the protein is affected by mutation.
Mutations of MECP2 leading to RTT
At the moment, several hundred different mutations
have been reported leading to RTT by loss or impaired
function of MECP2 protein due to truncation, abnormal
folding, or binding instability [25] (see also MECP2 var-
ieties on LOVD database [71]). This contributes to the
variety of RTT phenotype and symptom severity.
The effects of total absence of MECP2 protein were
investigated in several model systems. Deletion of
MECP2 from glial cells had only mild phenotypic conse-
quences [72]. In a mouse model specific deletion of
MECP2 in the forebrain caused behavioral abnormalities,
limb clasping, impaired motor coordination, anxiety, and
abnormal social behavior but not locomotor activity or
changes in fear conditioning [73]. In another mouse
model, silencing MECP2 in GABAergic neurons led to
severe RTT like phenotype [74].
Sixty-seven percent of all MECP2 mutations found
in humans are in eight hot spots: R106 (correspond-
ing RS number from dbSNP: rs28934907), R133
(rs28934904), T158 (rs28934906), R168 (rs61748427),
R255 (rs61749721), R270 (rs61750240), R294
(rs61751362) and R306 (rs28935468). Most of the
mutations which cause RTT occur in the MDB re-
gion of MECP2 [70] (Fig. 1). A 100-fold reduction of
binding affinity of MECP2 to methylated DNA is
documented for the mutations R106W (rs28934907),
R133C (rs28934904), and F155S (rs28934905) and
binding affinity reduction of about 2-fold was found
in mutation T158M (rs28934906) [45].
The most important metabolites, genes and
pathways affected by MECP2 in RTT
The examination and investigation of RTT females (and
model systems) revealed that an impaired MECP2 influ-
ences biological pathways on many levels. Several genes
have been found to be increased or decreased in expres-
sion, levels of various metabolites are changed and sev-
eral biological pathways were found to be typically
affected although the molecular mechanisms are not yet
clear. In this chapter the main metabolites, genes and
pathways which are influenced or changed by RTT are
summarized and as far as known integrated in the
MECP2 mechanistic pathway (Fig. 2). For getting these
results, samples from human RTT females were often
used but many results come from studies with Mecp2-/y
mice (e.g. the Bird model [75]). These mice do not ex-
press Mecp2 at all and they display the same symptoms
as humans, such as normal development until about
6 weeks, regression, reduced movement, clumsy gait, ir-
regular breathing, and the mice have a reduced life span
of about 3 months. Postmortem analysis revealed re-
duced brain and neuronal cell size which is similar to
observations in humans. Other mouse strains or in vitro
models with mutated MECP2, reduced or overexpressed
MECP2 levels are also commonly used to study RTT.
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Recently, researchers started to use iPSCs (induced pluri-
potent stem cells) from human or murine origin [76].
Metabolites
Early autopsies revealed reduced levels of catechol-
amines, namely dopamine, serotonin and norepinephrine
while markers for bioaminergic metabolism in general
were higher [77, 78] (summary of metabolites in Table 2
and see also the list of metabolites on WikiPathways
[18] (pathway ID 3584). This was confirmed by a study
of Panayotiset al. [79] who revealed time-dependent
levels of dopamine, norepinephrine, serotonin, and their
catabolites in the brain tissues of Mecp2-/y mice. Viemari
[80] et al. showed that Mecp2-/y mice have a deficiency
in norepinephrine and serotonin content in the medulla
and a drastic reduction of medullary TH (catecholamine
producing) neurons indicating that dysfunctional neur-
onal development may be the reason for decreased cat-
echolamine levels. The phosphorylation of MECP2 is
triggered by neuronal activity which is caused by release
of neurotransmitters (Fig. 2). Hutchinson et al. [81]
demonstrated that phosphorylation of MECP2 is
dependent on dopamine, serotonin and norepinephrine
activated pathways (Fig. 2, MECP2 phosphorylation).
Another metabolite shown to be present in high levels
in RTT females is glutamate. Increased glutamate pro-
duction (or decreased glutamate consumption) may lead
to over excitation of glutamatergic neurons and can
trigger increased uptake and conversion of glutamate to
glutamine. Over excitation feedback may cause the
downregulation of the glutamate receptor which was
observed before [82]. Moreover, severe downregulation
in gene expression for the glutamate D1 receptor
GRID1 (GluD1) was found (Fig. 2). This receptor links
post and presynaptic compartments and influences not
only synapsis function but also neuronal differentiation
[83]. Glutamate levels during sleep-wake cycle were
also affected in Mecp2 deficient mice [84]. Additionally,
BDNF, which is directly regulated by MECP2, is also
known to regulate GRID1 expression [85]. Glutamate
disposal is energy consumptive which may help explain
the increased level of energy metabolism found in
brains of Mecp2-/y mice and RTT females in neuroim-
aging studies [86].
A metabolomics investigation found changed
phospholipid profiles in Mecp2-/y mice [82]. Phospho-
lipid metabolism is directly associated with cell
growth since it provides membrane material for inner
and outer hull structure. Still, it remains unclear
whether this is the cause or just one of the conse-
quences of reduced neuronal cell size and network
connectivity of RTT. But as MECP2 basic function is
global transcription dampener in combination with
activity dependent activation of transcription this sug-
gests that reduced membrane material production is a
consequence of lack of activity specific transcription
activation.
Genes/gene products
MECP2 is a global transcription and translation influen-
cing factor but there are also single specific genes which
are found to be up- or downregulated in the absence of
functional MECP2. The expression of the MECP2 target
genes is affected in human, mouse and in vitro models.
In the absence of functional MECP2 the expression of
BDNF, GAMT, DLX5, DLX6, FKBP5, SGK1, FXYD1 and
MPP1 is upregulated whereas the expression of UBE3A
[25] and GRID1 [83] are downregulated (Table 3 and see
also the list on pathway 3584 [18]). BDNF, which shows
in all investigated models the most consistent effect, is a
MECP2 regulated protein and it is necessary for neur-
onal development and function, too (Table 3). The
BDNF molecular pathway and its influence on neuronal
development and function is currently the best investi-
gated. For GAMT it is known that this gene is involved
in creatine metabolic and biosynthetic process which
was found to be dysregulated in some (not all) Rett fe-
males and may cause or consequence to breathing prob-
lems [4]. DLX5 and DLX6 are homeobox genes and
involved in regulation of gene expression in general.
DLX5 is especially responsible for ectodermal differenti-
ation processes. The activity of both is highly regulated
by methylation and for the maintenance of this methyla-
tion pattern MECP2 is required: binding sites for
MECP2 have been found in both promoters. There is an
ongoing discussion about DLX5 and DLX6 expression
being influenced by MECP2 deficiency [87], the final ar-
gument seems that it is at least true for DLX5 [88].
FKBP5 and SGK1 were identified as potential MECP2
targets because they are involved in regulation of
Table 2 Metabolites in RTT
Changes in RTT Metabolites
Increased levels [77–79] Catabolites of catecholamine metabolism,
glutamate
Decreased levels [77–80] Dopamine, norepinephrine (noradrenaline),
serotonin, melatonin, myo-inositol,
phospholipids, GABA
Table 3 Genes, which are up- or downregulated in human or
model system without functional MECP2
Changes in RTT Genes
Upregulated [25, 89, 90] BDNF, FKBP5, IGF2, DLX5, DLX6,
SGK1, MPP1, GAMT, FXYD1
Downregulated [25, 83] UBE3A, GRID1
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glucocorticoid responding gene regulation (stress re-
sponse). Mecp2-0 mice showed anxiety behavior, had el-
evated levels of those transcripts but normal levels of
glucocorticoids [89]. FXYD1 is a transmembrane modu-
lator of Na+/K+ -ATPase activity involved in neurite out-
growth. It was found to be overexpressed in a Mecp2-0
mouse model inhibiting neuronal growth [90] and re-
duced arborization is generally found in RTT. MPP1
(signal transduction, neuronal homeostasis) and IGF2
(cell proliferation) were identified in a transcriptomics
expression study to be strongly overexpressed in a
study with human lymphoblastoid cells of Rett pa-
tients and controls [91]. MECP2 interacts with E6AP,
the protein of the UBE3A gene and they are regulat-
ing the expression of several target genes [92]. GRID1
encodes for glutamate D1 receptor (GluD1) and is
downregulated in the absence of functional MECP2
[83]. Glutamate receptors play a major role in neur-
onal signal transduction.
Pathways
Bedogni et al. mentioned the difficulty to identify unique
target pathways of MECP2 because MECP2 is both a re-
pressor and an activator of transcription and the balan-
cing and timing of transcription levels seems to
contribute more to disorder development than activation
of single pathways [70]. Several transcriptomics studies
using samples from RTT females, mouse and in vitro
model systems showed about 60 significantly enriched
pathways, for example inflammation, MAPK signaling,
ERBB signaling, neurotropin intracellular cascade, sterol
biosynthesis [93], cholesterol metabolism [93], cytoskel-
eton formation, and apoptosis [70].
While animal and in vitro models often use MECP2 –
KO models (e.g. Mecp2-/y mouse) human RTT patient
derived samples often have a residual MECP2 activity
due to the various mutations which impair the function
rather than inhibiting the expression completely. Tanaka
et al. [76] investigated gene expression profiles of iPSC
lines derived from six different RTT females with differ-
ent MECP2 mutations. They created and compared ex-
pression profiles of two iPSCs cell lines derived from
each of the patients, one with the X chromosome active
that has the wild type MECP2 and the other one with
the chromosome with the mutated gene. The differently
expressed genes and altered pathways are very differ-
ent for each patient. This is an interesting result, as
there are so many different MECP2 mutations which
lead to RTT. A specific mutation affects protein func-
tion differently and may trigger different pathways
leading to different phenotypes. Linking genetic data
to molecular analysis (transcriptome, metabolome)
and phenotype will be a future challenge to elucidate
the pathways of RTT.
MECP2-related pathways involved in RTT
phenotypes
In this chapter we discuss how mutated MECP2 leads to
failure in neuronal synapsis formation and function
which are one of the major causes of RTT phenotype.
MECP2 acts in a biological (molecular) network of con-
stant interaction by regulating and being regulated. This
complex molecular network interaction leads to effects
in cellular morphology (e.g. arborization), synapsis func-
tion and neuronal network growth, development, and
maintenance.
According to Lyst and Bird [9] MECP2 mutations
cause RTT by disrupting two major functions: 1. co-
repressor recruitment, and 2. chromatin compaction,
which are both basic molecular functions. Skene and
Bedogni specified this assumption of MECP2 function as
a global dampener of transcription in neurons plus the
activity dependent transcription activation which leads
to proper synapsis function and development [43, 70].
The differences in global gene expression of RTT and
wild-type control groups are not substantial – neither in
fold change nor number of genes differently expressed -
indicating that more subtle dysregulation events in sev-
eral pathways are responsible for RTT [62, 94–97].
MECP2 is a global repressor of transcription [43], a glo-
bal activator of gene translation [61] and it reacts on
neuronal pathway signals which lead to phosphorylation
of MECP2 and detachment from DNA. Therefore,
MECP2 dampens neuronal transcription globally and al-
lows activity related responses which seem to be neces-
sary for learning activity and specific synapsis formation
[98]. Bedogni et al. found a direct connection between
MECP2 and molecular pathways leading to cytoskeleton
re-formation [70] indicating structural changes leading
towards neuronal network formation. BDNF and FXYD1
seem here to be the link between MECP2 and the cellu-
lar phenotype [90]. Li et al. found in human embryonic
stem cells, which are developing from stem cells to
neuronal precursor cells to neurons, that in a premature
state, MECP2 acts as an activator of transcription while
transcription repressor activity was only found in mature
neurons [61]. The levels of MECP2 start to increase
postnatally and the protein is quite abundant in mature
nervous systems [43, 99]. The expression of MECP2 is
not uniform in different neuronal cell populations [100],
parts of the brain and changes with age [101]. Mouse
Mecp2-KO neuronal precursor cells are not different
from wildtype ones in respect to expression patterns,
proliferation, and differentiation (morphology), they
change only during maturation [99]. Together with the
observation that symptoms of RTT do not appear before
about month 6, this led to the assumption that MECP2
has less to do with neurogenesis but more with neuronal
function and maintenance, and synapsis formation and
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function. This may explain why the RTT phenotype be-
comes visible only at the quite late age of 6–18 months.
In RTT females brains a decreased number of synapsis
was found [102–104]. Synaptogenesis again is mostly ob-
served in the period of RTT symptom development
(month 6 – 18) which may explain the development of
learning disability. In MECP2 null mouse model reduced
neuronal differentiation [105] and synaptic deficits [98]
were observed. Mice studies and postmortem brains of
RTT females reveal alterations in neuron structures
which may be due to decreased dendritic complexity be-
cause of an immature synaptic spine morphology leading
to malfunction of synaptic development and plasticity
[106–108]. Changed neuronal tubulin expression was
found directly in the brain tissue of RTT and Angelman
syndrome patients [109]. Dysfunctional MECP2 led also
to changes in synaptic transmission, short and long-term
synaptic plasticity, deficits in short and long term po-
tentiation (LTP and LTD) in mice [110].
The abnormal levels of neurotransmitters and differ-
ently expressed neurotransmitter receptors lead to an
imbalance between excitatory and inhibitory neuronal
activity (namely imbalance of GABAergic, glutamatergic
and dopaminergic neuronal pathways). Such abnormal
ratio of excitation/inhibition in brain activity was also
found in autistic patients before [111–113] and it is a
known effect in Parkinson’s disease which shares the
motoric disabilities with RTT [114]. The gene in the
neurotransmitter pathway which is known to be down-
regulated in the absence of functional MECP2 is GRID1
which could here be the link between mutation and
phenotype [83]. RTT models using murine and human
induced pluripotent stem cells showed some RTT fea-
tures and these symptoms were documented for MECP2
overexpression models, too, leading again to the as-
sumption that MECP2 function is dose dependent [26].
In summary, MECP2 affects epigenetic regulation of
gene expression, which changes neurobiological activity,
network formation and function which causes the major
phenotype.
Current gaps in understanding RTT pathways
Although these processes could indeed explain many
neuronal function related symptoms of RTT there is still
lack of evidence for other phenotypes, especially those
which occur in many but not in all RTT females. 1)
Breathing patterns: breathing is regulated by brain stem
function which gets its signals from receptors for blood
pH, carbon dioxide and (to a lower amount) oxygen
levels. Abnormal RTT breathing patterns could be
Table 4 Olfactory vs. visual system: tissue specific MECP2 influence
Olfactory epithelium Visual system
Observation: A study on olfactory bulb biopsies of RTT females revealed
less olfactory receptors indicating less sensitive olfactory sense [119]. The
olfactory epithelium in postnatal rodents experiences strong upregulation
of MECP2 [120, 121].
Observation: Vertebrate eyes are originally specialized brain tissue.
Though being expected to be subjected to MECP2 dysfunctionality
symptoms the visual system, retina, visual nerve and visual cortex
seem to be less affected by RTT. Patients are able to focus, blink,
eye-track, and do not perform worse in visual tests than healthy
population [122]. Their families report often that they are using eye
contact as communication method and therefore eye tracking
systems are a promising method to improve communication.
Molecular/histological data: MECP2 deficiency induces also an
imbalance in glutamatergic/GABAergic innervation in the olfactory
bulb. The excitation in MECP2 KO mice is reduced and there is
generally an imbalance between excitatory and inhibitory pathways
observed leading to premature death of olfactory neurons in RTT
mice models [121]. MECP2 seems to regulate the activity dependent
transcriptional responses in olfactory sensory neurons the same way
as in central nervous system and model systems [123]. This cycle of
neuronal activity dependent transcription activation (fast feedback
loop based on Ca2+/calmodulin) seems to be responsible for neuronal
circuitry refinement, playing a role in olfactory sensory nerve
maturation and olfactory learning. MECP2 affects the expression of
olfactory sensory cell adhesion molecules KIRREL2 and PCHD20
directly, KIRREL3, and CNTN4 indirectly. It represses KIRREL2 but is
required for activity dependent upregulation of KIRREL2 after odor
stimulation [123]. KIRREL3 is an autism related gene [124] and the
family of KIRREL genes is known to be widely expressed in neuronal
tissue for synaptogenesis and synaptic specificity [125].
Molecular/histological data: Jain et al. investigated ocular MECP2
expression in post mortem brains of RTT females and compared it to
healthy controls. Although the RTT females show the typical severe
neurological deficits their visual functions are well preserved. There
were no gross or microscopic aberrations detected and no significant
MECP2 level differences [101]. Another study investigating MECP2
expression levels in many neuronal and non-neuronal tissues found
MECP2 to be expressed weak or moderate in the nucleoplasm of
retinal cells while there were peaks of strong MECP2 presence in
chromocenters [126]. Although it was shown in a previous study
with MECP2 KO mice that their visual system (acuity) is affected with
disorder onset [127] and visual systems also need refinement by
circuits and MECP2 dependent synapse remodeling [128] this was
not confirmed by the study of Song et al. [126]. Their retina samples
from MECP2 deficient mice did not show any differences to control
concerning immunochemical markers, cellular and histological
anatomy, synapsis formation and neurotransmitters [126].
Conclusion: Data indicates that the olfactory sense is less functional
in Rett females due to the strong dependency of the molecular
signal processing pathways on MECP2.
Conclusion: Together with the measured visual performance in
human RTT females [122] these observations indicate that MECP2
surprisingly does not play a major role in ocular function.
Gap: Why is the olfactory sensory system affected in RTT females?
Is there a measurable difference in response to olfactory stimulants
of Rett females and controls?
Gap: What is the mechanistic explanation of the rather unaffected
visual system? Why do neuronal cells of the visual system not need
MECP2 for proper function?
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caused by neuronal dysfunction of the brain stem or
neuronal pathways but metabolic dysregulation involving
abnormal creatine levels due to GAMT over/under ex-
pression is also an influencing factor [4]. GAMT is one
of the MECP2 downstream activated genes. 2) Cardiac
abnormalities: Heart beat is generally regulated by cen-
tral nervous system but has its own nerve knots for sig-
nal production, too. Specialized neurons in the heart
ensure proper electric signal transition. These might be
affected by RTT directly, by brain stem function, or
both. RTT patients are indeed known for higher inci-
dence of sudden death and heart problems like tachy-,
brady- and arythmia were observed before (. Further-
more, vascular dysfunctions have been found which are
directly related to MECP2 dysfunction although the mo-
lecular pathway between MECP2 and effector genes is
not yet elucidated [115]. 3) Digestion and nutrient up-
take problems: Stomach and intestines are covered with
a complex network of nerve cells. Dysfunctional nerve
cells may lead to constipation and malabsorption of nu-
trients, e.g. Vitamin D but there may also be other nutri-
ent processing pathways involved. 4) Tissue specific
effects: Tissue specific neuronal cells are differently in-
fluenced by MECP2 mutation, e.g. olfactory sensory vs.
visual system (Table 4). Recently it was found that
MECP2 mutations contribute to hypersensitivity of
mechanoreceptors [116] which aligns with the observa-
tion of clinicians and caregivers. It is currently unknown
in which neuronal cell subpopulations MECP2 is more
or less necessary for normal function although there are
indications that there are differences [100].
To understand these processes integration of different
levels of biological knowledge and research results is ne-
cessary, and interactive biological pathways help to
organize, analyze, and visualize existing knowledge. To
integrate the information the exact mutation of MECP2
gene needs to be combined with molecular data (e.g.
gene expression data, metabolomics) and a detailed
description of the RTT females’ phenotype (including
clinical laboratory measurements). This process will in-
crease the understanding of the underlying pathways of
the variety of RTT phenotypes. Gathering this know-
ledge and bringing it properly together needs collabor-
ation of biomedical and bioinformatics researchers,
physicians and patients [117]. Furthermore, knowing the
essential pathways and their components which contrib-
ute to a certain phenotype or symptom may lead to the
discovery of drug targets. These are not likely to be able
to cure RTT itself but may help to reduce the severity of
specific symptoms.
Conclusions
The present review summarizes the current knowledge
about MECP2 structure and function, how it influences
levels of metabolites, gene expression and biological
pathways, and tries to bridge the different types of data
available to explain the development of typical RTT
phenotype by visualizing in form of a pathway (Fig. 2).
Although the dysregulation events in neuronal cells can
be already be explained quite well, the mechanistic ex-
planation of several additional symptoms is still missing.
Integrating the knowledge about the individual muta-
tion, molecular data and phenotype information will
help to find biological pathways and therefore explana-
tions for these symptoms. Finding the right target genes,
proteins, or metabolites can build a bridge between
genotype and phenotype, and possibly to drug targets
and pathways like this will be a great help in
visualization and analyses.
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